Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Federica Cocito
Observed names:
F Cocito,
F. Cocito
Institution:
Azienda Ospedaliera San Gerardo
Observed institutions:
University of Pavia,
Azienda Ospedaliera San Gerardo,
Fondazione Gimema Onlus,
Policlinico San Matteo Fondazione,
University of Milano-Bicocca
ORCID:
0000-0002-8700-8229
Observed ORCID:
0000-0002-8700-8229
OpenAlex ID:
A5045956606
Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice
2016
·
Artur Jurczyszyn
, Norbert Grzasko
, et al.
·
American Journal of Hematology
·
156
PDF
A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma
2016
·
N Bolli
, Y Li
, et al.
·
Blood Cancer Journal
·
89
PDF
The possible role of burden of therapy on the risk of myeloma extramedullary spread
2016
·
Silvia Mangiacavalli
, A. Pompa
, et al.
·
Annals of Hematology
·
49
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome
2021
·
Anna Dodero
, Anna Guidetti
, et al.
·
Haematologica
·
45
PDF
Psychological care of caregivers, nurses and physicians: a study of a new approach
2014
·
Maurizio S. Abeni
, Margherita Magni
, et al.
·
Cancer Medicine
·
37
PDF
Monoclonal gammopathy of undetermined significance: a new proposal of workup
2013
·
Silvia Mangiacavalli
, Federica Cocito
, et al.
·
European Journal Of Haematology
·
33
Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide
2014
·
Vittorio Montefusco
, Monica Galli
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
27
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients
2013
·
Alessandra Larocca
, Sara Bringhen
, et al.
·
Blood
·
25
PDF
Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study
2024
·
Chiara Malinverni
, Andrea Bernardelli
, et al.
·
Blood
·
21
Effects of blocking CD24 and CD47 ‘don't eat me’ signals in combination with rituximab in mantle‐cell lymphoma and chronic lymphocytic leukaemia
2023
·
Andrea Aroldi
, Mario Mauri
, et al.
·
Journal of Cellular and Molecular Medicine
·
21
Changing Pattern of Presentation in Monoclonal Gammopathy of Undetermined Significance: A Single-Center Experience With 1400 Patients
2010
·
Marzia Varettoni
, Alessandro Corso
, et al.
·
Medicine
·
20
CD24/Siglec-10 "Don't Eat Me" Signal Blockade Is a Potential Immunotherapeutic Target in Mantle-Cell Lymphoma
2021
·
Andrea Aroldi
, Mario Mauri
, et al.
·
Blood
·
17
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
2023
·
Manuel Gotti
, Roberta Sciarra
, et al.
·
HemaSphere
·
16
Long Term Evaluation of the Impact of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: A Cost-Effectiveness Analysis
2013
·
Alessandro Corso
, Silvia Mangiacavalli
, et al.
·
PLoS ONE
·
16
PDF
Correlation between burden of 17 P 13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma
2013
·
Silvia Mangiacavalli
, Lara Pochintesta
, et al.
·
British Journal of Haematology
·
14
PDF
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study
2016
·
Samantha Pozzi
, Massimo Gentile
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
12
Implemented myeloma management with whole-body low-dose CT scan: a real life experience
2016
·
Silvia Mangiacavalli
, Sara Pezzatti
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
11
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B‐MuD) for the treatment of relapsed multiple myeloma
2012
·
Silvia Mangiacavalli
, Lara Pochintesta
, et al.
·
American Journal of Hematology
·
8
PDF
Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice
2019
·
Federica Cocito
, Silvia Mangiacavalli
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
7
Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi
2023
·
Gloria Margiotta-Casaluci
, Sara Bigliardi
, et al.
·
Frontiers in Oncology
·
6
PDF
Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma
2011
·
Silvia Mangiacavalli
, Giovanni Albani
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
5
Corneal sub-basal neural damage pattern in multiple myeloma patients treated with bortezomib: anin vivoconfocal study
2015
·
Federica Cocito
, Gabriella Ricciardelli
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
4
Anti-CD20 maintenance strategies to face the challenge of COVID-19 pandemic in follicular lymphoma: results from the R-FolSTOP multicentre Italian study
2025
·
Alessia Castellino
, Lorenzo Comba
, et al.
·
Annals of Hematology
·
3
High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies
2024
·
Simonetta Viviani
, Anna Vanazzi
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
3
Efficacy and Safety of Ibrutinib in Relapsed or Refractory Marginal Zone Lymphomas: The “Real World” Italian Experience
2023
·
Michele Merli
, Antonella Anastasia
, et al.
·
Blood
·
3
PDF
Show more works
View as search
Works count:
70
Citation count:
682
H-index:
14
I10-index:
17
Year
Topic
Type